Product Description
Imatinib mesylate 220127-57-1
AI Product Description
*The following content is generated by AI and is for reference only.
Imatinib mesylate, commonly known by its brand name Gleevec or Glivec, is a cornerstone medication in the field of oncology, specifically revolutionizing the treatment of chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). First approved by regulatory agencies in the early 2000s, this compound represents a paradigm shift from traditional cytotoxic chemotherapy to targeted therapy. Its chemical identity is defined by the molecular formula C29H31N7O·CH4O3S, reflecting the combination of the active imatinib base with methanesulfonic acid. The unique CAS registry number for Imatinib mesylate is 220151-56-8, which serves as its definitive identifier in global chemical databases.
The primary mechanism of action involves the inhibition of specific tyrosine kinases, most notably the BCR-ABL fusion protein. This abnormal protein is generated by a chromosomal translocation known as the Philadelphia chromosome, which drives uncontrolled cell division in leukemic cells. By binding to the ATP-binding site of these kinases, imatinib blocks the phosphorylation process essential for tumor growth and survival, effectively inducing apoptosis in cancer cells while sparing healthy tissue to a significant degree compared to conventional treatments. Beyond CML, it is also indicated for gastrointestinal stromal tumors (GIST) caused by mutations in the c-KIT gene and for systemic mastocytosis.
As a small molecule inhibitor, imatinib mesylate is administered orally, typically in tablet form, offering patients a convenient treatment regimen that can be managed at home. While generally well-tolerated, common side effects may include fluid retention, nausea, muscle cramps, and fatigue. Despite these manageable adverse events, the drug has dramatically improved long-term survival rates for patients with CML, transforming what was once a fatal diagnosis into a manageable chronic condition for many. Ongoing research continues to explore its efficacy in other malignancies, solidifying its status as a critical pillar in modern precision medicine and personalized cancer care strategies worldwide.